Met (also known as HGFR), through its positive crosstalk with HER2, contributes to tumor aggressiveness, migration, proliferation, and chemoresistance by upregulating MAPK, WNT, and PI3K/AKT pathways [40]. The gene discussed is ERBB2; the disease is neoplasm.